线粒体自噬与糖尿病心肌病

摘要/Abstract

摘要： 糖尿病心肌病(diabetic cardiomyopathy,DCM)是一种与糖尿病(Diabetes Mellitus,DM)有关的心肌病,主要表现为心功能不全、心肌肥大、心肌纤维化等症状,严重者甚至出现心力衰竭,是导致患者死亡的常见原因。研究其发生机制对明确疾病进而针对原因靶点治疗有着重要意义。近年来线粒体自噬、细胞焦亡、铜死亡、铁死亡等成为研究热点。本文针对糖尿病心肌病中线粒体自噬的分子机制及治疗展开综述。

张宁, 王立彬. 线粒体自噬与糖尿病心肌病[J]. 心血管病防治知识, 2026, 16(8): 142-144.

参考文献

[1] Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study[J]. BMJ, 2020,369: m997.
[2] Rubler S, Dlugash J, Yuceoglu YZ, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis[J]. Am J Cardiol, 1972,30(6): 595-602.
[3] Trost SU, Belke DD, Bluhm WF, et al. Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy[J]. Diabetes, 2002,51(4): 1166-1171.
[4] Lin J, Duan J, Wang Q, et al. Mitochondrial Dynamics and Mitophagy in Cardiometabolic Disease[J]. Front Cardiovasc Med, 2022,9: 917135.
[5] Zhi F, Zhang Q, Liu L, et al. Novel insights into the role of mitochondria in diabetic cardiomyopathy: molecular mechanisms and potential treatments[J]. Cell Stress Chaperones, 2023,28(6): 641-655.
[6] Ketenci M, Zablocki D, Sadoshima J. Mitochondrial Quality Control Mechanisms during Diabetic Cardiomyopathy[J]. JMA J, 2022,5(4): 407-415.
[7] Lemasters JJ. Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging[J]. Rejuvenation Res, 2005,8(1): 3-5.
[8] Titus AS, Sung EA, Zablocki D, et al. Mitophagy for cardioprotection[J]. Basic Res Cardiol, 2023,118(1): 42.
[9] Bharath LP, Rockhold JD, Conway R. Selective Autophagy in Hyperglycemia-Induced Microvascular and Macrovascular Diseases[J]. Cells, 2021,10(8):2114.
[10] Lu Y, Li Z, Zhang S, Zhang T, et al. Cellular mitophagy: Mechanism, roles in diseases and small molecule pharmacological regulation[J]. Theranostics, 2023,13(2): 736-766.
[11] Narendra DP, Jin SM, Tanaka A, et al. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin[J]. PLoS Biol, 2010,8(1): e1000298.
[12] Jin SM, Lazarou M, Wang C, et al. Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL[J]. J Cell Biol, 2010,191(5): 933-942.
[13] Lazarou M, Jin SM, Kane LA, et al. Role of PINK1 binding to the TOM complex and alternate intracellular membranes in recruitment and activation of the E3 ligase Parkin[J]. Dev Cell, 2012,22(2): 320-333.
[14] Yang C, Xiao C, Ding Z, et al. Canagliflozin Mitigates Diabetic Cardiomyopathy through Enhanced PINK1-Parkin Mitophagy[J]. Int J Mol Sci, 2024,25(13).
[15] Li X, Liu J, Lu Q, et al.AMPK: a therapeutic target of heart failure-not only metabolism regulation[J]. Biosci Rep, 2019,39(1).
[16] Deleyto-Seldas N, Efeyan A. The mTOR-Autophagy Axis and the Control of Metabolism[J]. Front Cell Dev Biol, 2021,9: 655731.
[17] Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, et al. Raptor, a positive regulatory subunit of mTOR complex 1, is a novel phosphoprotein of the rDNA transcription machinery in nucleoli and chromosomal nucleolus organizer regions (NORs)[J]. Cell Cycle, 2011,10(18): 3140-3152.
[18] Wu CW, Storey KB. mTOR Signaling in Metabolic Stress Adaptation[J]. Biomolecules, 2021,11(5):681.
[19] Chomanicova N, Gazova A, Adamickova A,et al. The role of AMPK/mTOR signaling pathway in anticancer activity of metformin[J]. Physiol Res, 2021,70(4): 501-508.
[20] Garami A, Zwartkruis FJ, Nobukuni T,et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2.[J]. Mol Cell, 2003,11(6): 1457-1466.
[21] van Veelen W, Korsse SE, van de Laar L, et al. TPeppelenbosch MP. The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling[J]. Oncogene, 2011,30(20): 2289-2303.
[22] Wang H, Wang L, Hu F, et al. Neuregulin-4 attenuates diabetic cardiomyopathy by regulating autophagy via the AMPK/mTOR signalling pathway[J]. Cardiovasc Diabetol, 2022,21(1): 205.
[23] Guo Z. The role of glucagon-like peptide-1/GLP-1R and autophagy in diabetic cardiovascular disease[J]. Pharmacol Rep, 2024,76(4): 754-779.
[24] Tere?ak P, Lapao A, Subic N,et al. Regulation of PRKN-independent mitophagy[J]. Autophagy, 2022,18(1): 24-39.
[25] Poole LP, Bock-Hughes A, Berardi DE, et al. ULK1 Promotes Mitophagy via Phosphorylation and Stabilization of BNIP3[J]. Sci Rep, 2021,11(1): 20526.
[26] Wu W, Tian W, Hu Z, et al. ULK1 translocates to mitochondria and phosphorylates FUNDC1 to regulate mitophagy[J]. EMBO Rep, 2014,15(5): 566-575.
[27] Murakawa T, Okamoto K, Omiya S, et al. A Mammalian Mitophagy Receptor, Bcl2-L-13, Recruits the ULK1 Complex to Induce Mitophagy[J]. Cell Rep, 2019,26(2): 338-345.
[28] Wang Y, Liu W, Liu C, et al. Asprosin attenuates diabetic cardiomyopathy through inhibiting autophagy mediated by AMPK/mTOR/ULK1 pathway[J]. Am J Physiol Cell Physiol, 2025,329(2): C377-C394.